Satralizumab Continues to Display Long-Term Efficacy in AQP4-IgG-Seropositive NMOSD.

Published Date: 15 Oct 2023

The SAkuraMoon study's annual relapse rate was consistently low in patients receiving satralizumab, according to a recent analysis, and a sizable portion of patients did not experience mild relapses, severe relapses, or worsening disability.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.

2.

Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness

3.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

4.

According to a study, taking part in a clinical trial for cancer may not actually increase survival.

5.

A new blood test greatly increases the ability to detect cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot